The influence of drug-like concepts on decision-making in medicinal chemistry.
about
Potent and specific inhibition of glycosidases by small artificial binding proteins (affitins)Genome-wide assessment of the carriers involved in the cellular uptake of drugs: a model system in yeastHow drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionLost in Translation (LiT): IUPHAR Review 6Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesNitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophoreDrug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening MethodologiesCase Characterization, Clinical Features and Risk Factors in Drug-Induced Liver InjuryDiversity-oriented synthetic strategies applied to cancer chemical biology and drug discoveryStructure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive reviewThe ChEMBL bioactivity database: an updateMetabolomics and systems pharmacology: why and how to model the human metabolic network for drug discoveryThermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitorsIdentification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived HitDissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein InterfaceUsing a Fragment-Based Approach To Target Protein-Protein InteractionsBiophysical Fragment Screening of the β 1 -Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug DesignDiscovery of Plasmodium vivax N -Myristoyltransferase Inhibitors: Screening, Synthesis, and Structural Characterization of their Binding ModeStructure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic propertiesDesign and Synthesis of High Affinity Inhibitors of Plasmodium falciparum and Plasmodium vivax N -Myristoyltransferases Directed by Ligand Efficiency Dependent Lipophilicity (LELP)4-Acyl pyrroles: mimicking acetylated lysines in histone code readingN-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular ActivityIDAAPM: integrated database of ADMET and adverse effects of predictive modeling based on FDA approved drug dataRational methods for the selection of diverse screening compoundsIron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseasesIn silico modeling of human α2C-adrenoreceptor interaction with filamin-2What can we learn from the evolution of protein-ligand interactions to aid the design of new therapeutics?Use of natural products as chemical library for drug discovery and network pharmacologyDrug Promiscuity in PDB: Protein Binding Site Similarity Is KeyA new in vivo screening paradigm to accelerate antimalarial drug discoveryIdentification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaignExploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation AssaysIdentification of New Molecular Entities (NMEs) as Potential Leads against Tuberculosis from Open Source Compound RepositoryChemical named entity recognition in patents by domain knowledge and unsupervised feature learningDefining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributesMolecular descriptor data explain market prices of a large commercial chemical compound libraryAnalysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffoldsPortfolio Decisions in Early DevelopmentConstraining cyclic peptides to mimic protein structure motifs.How many molecules does it take to tell a story? Case studies, language, and an epistemic view of medicinal chemistry.
P2860
Q21090623-94385BF6-AB0E-40F7-A8FF-6D8A20317A8FQ21245306-F214005E-E9EE-4BE0-97DE-5499DC5DB850Q24273350-81453794-5CF8-4BDF-BFC1-7D5BA27929A9Q24289150-099D6931-F4BA-49B8-B8F9-6A2B39DF8B18Q24289511-C4DF0767-9C8F-4545-9D68-222A3D0E4DC9Q24569706-140F555E-1E71-4601-A0A1-3927FF69243AQ26745421-693D2F28-3FC2-40D9-92A8-1C06E1AB45B5Q26749054-746A4A7B-F329-4E94-A8A4-87D4D360A7D6Q26829081-DB3455D6-65DA-45BF-BF56-E6FF6331E4A8Q27008867-B73E243C-0BC9-4A96-AAB0-343FDAED943BQ27144224-8F9AB3A6-3DEB-4192-9AFC-3AC56488693EQ27144251-1C0BA5D8-E1B5-4AF1-B620-26DB62DC87FDQ27658036-08D25E47-D4D9-4E17-AE1A-340A5B2726B5Q27674710-EAB1AF78-8872-4568-B019-D57917333F31Q27674729-3C3AB5E1-D85A-45C5-8616-FEEF2EF9F2D7Q27675981-A8D3E693-0263-4EAE-9315-904BF4D6F860Q27676919-554C711A-2BF3-47CD-A0D5-322894442E03Q27678157-3CC17AB1-7C3B-4B00-B970-A9B9F8188386Q27678311-8B58FBA7-A7BD-49CE-9CE3-F28F7CC10FC5Q27682285-D27C94A8-7DD9-4334-81E6-F04B6C17DDB9Q27687671-55F98FB9-86CF-4D7B-8FE9-3DA4C87BBC6AQ27704211-F0F7C10F-04CE-4519-A31B-257BF20C871FQ27902312-923B6EC7-EC50-484C-85AB-D36DA5AF5325Q28303907-64DF250A-5F2B-49E1-BBA6-82D25CC4E042Q28388335-356E0AF6-D060-4C68-9AF1-691EF38A4002Q28392073-E2E7C196-9907-4B30-B272-E514795F6B3DQ28484296-C78999CF-A40C-450E-B7D8-6308D03B5633Q28487019-11B619AF-CE59-4F39-B66E-94A1A6B54A01Q28534178-1743B200-CFD3-4211-9FB6-B96AB7932E75Q28534314-67BE2171-0A56-4873-87F6-212933528D76Q28544017-9469392C-0B5F-4304-AC3E-1634A305C790Q28550025-1A257796-6721-472B-84B9-2F2DF3E77456Q28551394-599DAAFF-29D7-464A-A471-F2234E4334CBQ28604154-276EDC0C-4829-46C5-87B0-19784BDF3E6BQ28728799-A9D8F909-BC02-44C0-A45C-1C34CD1E25F8Q28829333-99FB629C-FB81-4146-BF01-07E4B2B4BA39Q29042705-A223B819-F791-4AB6-BB6E-CDF1BD8D030AQ29999056-FAAE8D1A-7344-4DEA-B024-7DC664297252Q30367509-2CB3F78C-0C65-4D57-A7CB-CFE4AA41A5E2Q30373202-F227162A-10CD-492B-AF83-DB0EBF9A7E2F
P2860
The influence of drug-like concepts on decision-making in medicinal chemistry.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The influence of drug-like concepts on decision-making in medicinal chemistry.
@en
The influence of drug-like concepts on decision-making in medicinal chemistry.
@nl
type
label
The influence of drug-like concepts on decision-making in medicinal chemistry.
@en
The influence of drug-like concepts on decision-making in medicinal chemistry.
@nl
prefLabel
The influence of drug-like concepts on decision-making in medicinal chemistry.
@en
The influence of drug-like concepts on decision-making in medicinal chemistry.
@nl
P356
P1476
The influence of drug-like concepts on decision-making in medicinal chemistry.
@en
P2093
Brian Springthorpe
Paul D Leeson
P2888
P304
P356
10.1038/NRD2445
P577
2007-11-01T00:00:00Z